Darzalex 400 mg (Daratumumab SOLUTION) 400 MG

DARZALEX 400 MG is a solution for intravenous use, containing the active ingredient daratumumab. This medication is commonly used in the management of certain hematologic conditions. It is manufactured by Janssen Inc. and originates from Canada.

Strength

400 MG

Pack Size

20ML

Manufacturer / TM Owner

JANSSEN INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

DARZALEX 400 MG is primarily used in the treatment of specific types of blood cancers. It works by targeting certain proteins on the surface of cancer cells, which can help the immune system recognize and destroy these cells. This medication is often prescribed for conditions where other treatments have not been effective.

Side Effects

Common effects of DARZALEX 400 MG may include infusion-related reactions, such as fever, chills, and shortness of breath. Some individuals may also experience fatigue, nausea, or an increased risk of infections. These effects can vary from person to person and may not affect everyone who uses this medication.

Precautions & Warnings

DARZALEX 400 MG should be administered under the supervision of a healthcare professional. It is important to inform your healthcare provider about any allergies or medical conditions you have before starting this treatment. Regular monitoring may be required to manage potential side effects and ensure the medication is working as intended.

Avoid Interactions

DARZALEX 400 MG may interact with certain medications, including those that suppress the immune system. It is important to discuss all current medications with your healthcare provider to avoid potential interactions. Alcohol and other substances that affect the immune system should also be used with caution.

References

Frequently Asked Questions

DARZALEX 400 MG is used in the treatment of certain types of blood cancers, often when other treatments have not been effective.

DARZALEX 400 MG is administered intravenously, typically under the supervision of a healthcare professional.

Common side effects may include infusion-related reactions, fatigue, nausea, and an increased risk of infections.

It is important to discuss all current medications with your healthcare provider to avoid potential interactions.

Individuals with certain allergies or medical conditions should consult their healthcare provider before using DARZALEX 400 MG.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.